Malvern, PA-based Vicept Therapeutics has nailed down a $10 million investment, wrapping a $16 million Series A to back its development of a topical therapy for rosacea. The developer says that it now has enough money to push through Phase I and Phase II trials on V-101. The Series A was led by Vivo Ventures, Sofinnova Ventures and Fidelity Biosciences. "We are focused on creating and developing novel products for use in the largest and fastest growing sectors of the dermatology market," said Neal Walker, president and chief executive officer of Vicept. Release